On February 4, 2016, the SEC instituted settled cease-and-desist proceedings against SciClone Pharmaceuticals, Inc. According to the SEC: "These proceedings arise out of violations of the anti-bribery, books and records and internal accounting controls provisions of Foreign Corrupt Practices Act of 1977 (the 'FCPA') [15 U.S.C. § 78dd] by SciClone concerning its pharmaceutical operations in China. From at least 2007 to 2012, employees of SciClone subsidiaries, who acted as agents of SciClone in conducting business in China, gave money, gifts and other things of value to foreign officials, including healthcare professionals ('HCPs') who were employed by state-owned hospitals in China, in order to obtain sales of SciClone pharmaceutical products. Various means were employed, and these schemes were known to and condoned by various managers within SciClone's China-based corporate structure. The related transactions were falsely recorded in SciClone's books and records as legitimate business expenses, such as sponsorships, travel and entertainment, conferences, honoraria, and promotion expenses. During this period, SciClone also failed to devise and maintain a sufficient system of internal accounting controls and lacked an effective anti-corruption compliance program."